amylin glp 1 dual agonist Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity | Diabetes Therapy GLP-1 and Amylin in the
Description
Goldstein BJ, Feinglos MN, Lunceford JK, et al

Deacon CF, Nauck MA, Toft-Nielsen M, et al.: Both subcutaneously and intravenously administered glucagonlike peptide I are rapidly degraded from the NH2-terminus in type lI diabetic patients and in healthy subjects

PMID: 2 AbererFHochfellnerDASourijHMaderJK

J Am Coll Cardiol 2024;84:1646-62.PubMed 98
The study results of the studies SURPASS-1 to SURPASS-5 have been published, and the remaining studies (SURPASS-6, SURPASS-CVOT, SURPASS-J-mono, SURPASS-J-combo
JNCI Cancer Spectr
